{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:14:34Z","timestamp":1777900474214,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006668","name":"Oregon Health & Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.gore.2026.102062","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:41:02Z","timestamp":1773826862000},"page":"102062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunotherapy induced sarcoidosis in a 47-year-old female with stage IIIC cervical cancer on pembrolizumab: A case report"],"prefix":"10.1016","volume":"64","author":[{"given":"Hanna","family":"O\u2019Neill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Bruegl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gore.2026.102062_b0005","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid\u2010like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.gore.2026.102062_b0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor\u2013associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.gore.2026.102062_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-247278","article-title":"Treatment-induced sarcoidosis in a patient with metastatic clear cell ovarian cancer","volume":"14","author":"DeCarli","year":"2021","journal-title":"BMJ Case Reports"},{"issue":"8","key":"10.1016\/j.gore.2026.102062_b0020","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2026.102062_b0025","first-page":"358","article-title":"Diagnosis and management of immune checkpoint inhibitor colitis","volume":"17","author":"Hashash","year":"2021","journal-title":"Gastroenterol. & Hepatol."},{"issue":"4","key":"10.1016\/j.gore.2026.102062_b0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4143\/crt.2013.45.4.354","article-title":"Sarcoidosis mimicking cancer metastasis following chemotherapy for ovarian cancer","volume":"45","author":"Kim","year":"2013","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.gore.2026.102062_b0035","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.crad.2022.09.127","article-title":"Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy","volume":"78","author":"Li","year":"2023","journal-title":"Clin. Radiol."},{"issue":"10460","key":"10.1016\/j.gore.2026.102062_b0040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gore.2026.102062_b0045","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/cancers14122937","article-title":"Sarcoid-like granulomatosis associated with immune checkpoint inhibitors in melanoma","volume":"14","author":"Melin","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.gore.2026.102062_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf017","article-title":"Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors","volume":"30","author":"Nykaza","year":"2025","journal-title":"Oncologist"},{"issue":"36","key":"10.1016\/j.gore.2026.102062_b0055","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102062_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107640","article-title":"Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival","volume":"227","author":"Smith","year":"2024","journal-title":"Respir. Med."},{"issue":"16_suppl","key":"10.1016\/j.gore.2026.102062_b0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e14623","article-title":"Clinical determinants and outcomes of hypothyroidism in immune checkpoint inhibitor (ICI) therapy","volume":"43","author":"Syed","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102062_b0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-Approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.gore.2026.102062_b0075","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41698-025-01123-0","article-title":"A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"9","author":"Wang","year":"2025","journal-title":"Npj Precis. Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:30:39Z","timestamp":1777631439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":15,"alternative-id":["S2352578926000421"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102062","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy induced sarcoidosis in a 47-year-old female with stage IIIC cervical cancer on pembrolizumab: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102062"}}